Sanofi successfully prices EUR 2 billion of bond issues
13 Marzo 2019 - 12:29PM
Sanofi successfully prices EUR 2
billion of bond issues
Paris, France - March 13, 2019 - Sanofi
announces that it has successfully priced its offering of EUR 2
billion of notes (the "Notes") across 3
tranches:
-
€850 million fixed rate notes, due March 2022,
bearing interest at an annual rate of 0.0%
-
€650 million fixed rate notes, due March 2029,
bearing interest at an annual rate of 0.875%
-
€500 million fixed rate notes, due March 2034,
bearing interest at an annual rate of 1.25%
The Notes are being issued off the
company's Euro Medium Term Note Programme.
The transaction enables the company to lower its average cost of
debt and extend the average maturity of its debt.
Sanofi intends to use the net proceeds of the offering for general
corporate purposes.
BofA - Merrill Lynch and Natixis acted as Global Coordinators and
Bookrunners, alongside ING and Santander which acted as Bookrunners
for the offering.
About Sanofi
Sanofi is dedicated to supporting people through their health
challenges. We are a global biopharmaceutical company focused on
human health. We prevent illness with vaccines, provide innovative
treatments to fight pain and ease suffering. We stand by the few
who suffer from rare diseases and the millions with long-term
chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is
transforming scientific innovation into healthcare solutions around
the globe.
Sanofi, Empowering Life
|
Media Relations Contact Quentin
Vivant
Tel.: +33 (0)1 53 77 46 46
mr@sanofi.com
|
Investor Relations Contact George
Grofik
Tel.: +33 (0)1 53 77 45 45
ir@sanofi.com
|
DISCLAIMER
This communication shall not constitute an offer
to sell or the solicitation of an offer to buy nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
The Notes have not been and will not be registered under the
Securities Act and may not be offered or sold within the United
States or to, or for the account or benefit of, U.S. persons except
in certain transactions exempt from the registration requirements
of the Securities Act.
PROHIBITION OF SALES TO EEA RETAIL INVESTORS - The Notes are not intended to be offered, sold or otherwise
made available to and should not be offered, sold or otherwise made
available to any Retail Investor in the European Economic Area
("EEA"). For these purposes, a "Retail Investor" means a person who
is one (or more) of: (i) a retail client as defined in point (11)
of Article 4(1) of Directive 2014/65/EU ("MiFID II"); or (ii) a
customer within the meaning of Directive 2002/92/EC ("IMD"), where
that customer would not qualify as a professional client as defined
in point (10) of Article 4(1) of MiFID II. Consequently no key
information document required by Regulation (EU) No 1286/2014 (the
"PRIIPs Regulation") for offering or selling the Notes or otherwise
making them available to retail investors in the EEA has been or
will be prepared and therefore offering or selling the Notes or
otherwise making them available to any retail investor in the EEA
may be unlawful under the PRIIPS Regulation.
This communication is only being distributed to and is only
directed at (i) persons who are outside the United Kingdom or (ii)
investment professionals falling within Article 19(5) of the
Financial Services and Markets Act 2000 (Financial Promotion) Order
2005 (the "Order") or (iii) high net worth companies, and other
persons to whom it may lawfully be communicated, falling within
Article 49(2)(a) to (d) of the Order or (iv) persons to whom an
invitation or inducement to engage in investment activity (within
the meaning of section 21 of the Financial Services and Markets Act
2000) may otherwise lawfully be communicated or cause to be
communicated (all such persons together being referred to as
"relevant persons"). The Notes are only available to, and any
invitation, offer or agreement to subscribe, purchase or otherwise
acquire such Notes will be engaged in only with, relevant persons.
Any person who is not a relevant person should not act or rely on
this document or any of its contents.
No Notes have been offered or sold nor will be offered or sold,
directly or indirectly, to the public in France; the Base
Prospectus or any other offering material relating to the Notes
have not been distributed or caused to be distributed and will not
be distributed or caused to be distributed to the public in France;
such offers, sales and distributions have been and shall only be
made in France to persons licensed to provide the investment
service of portfolio management for the account of third parties or
to qualified investors (investisseurs qualifiés) other than
individuals, investing for their own account, all as defined in
Articles L. 411-1, L. 411-2 and D. 411-1 of the French Code
monétaire et financier.
Sanofi Forward-Looking Statements
Any statements made in this communication that are
not statements of historical fact, including statements about
Sanofi's beliefs and expectations are forward-looking statements
and should be evaluated as such. Forward-looking statements include
statements that may relate to Sanofi's plans, objectives,
strategies, goals, future events, future revenues or performance,
and other information that is not historical information. Sanofi
does not undertake, and specifically disclaims, any obligation or
responsibility to update or amend any of the information above
except as otherwise required by law.
Additional Information:
This communication is neither an offer to purchase
nor a solicitation of any offer to sell any securities, nor shall
there be any sale of securities in any jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such
jurisdiction.
|
Press release (PDF)
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Sanofi via Globenewswire
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024